Technologies
PDF


WARF: P130052US03

Detecting Ovarian Cancer and Risk


INVENTORS -

Halcyon Skinner, Gary Schwartz

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing methods of screening serum calcium levels in women to identify and monitor those at higher risk for ovarian cancer.
OVERVIEWOvarian cancer is the most fatal gynecological cancer, killing 15,000 women in the Unites States every year. The overall five-year relative survival rate for women with ovarian cancer is 46 percent. The survival rate improves to 93 percent if the cancer is diagnosed early. Sadly, a fraction of cases are diagnosed at this curable stage.

Early diagnosis of ovarian cancer can be accomplished by measuring biomarkers in blood or urine. The most widely studied serum marker for ovarian cancer is CA125. Unfortunately, CA125 levels are elevated in only half of women with stage 1 disease. Also, screening is expensive and can lead to false positives and unnecessary surgeries.

There is great interest in finding new biomarkers that could help detect ovarian cancer at a curable stage.
THE INVENTIONA UW–Madison researcher and others have developed a new ovarian cancer screening method that measures total or ionized serum calcium levels in blood samples. Women exhibiting elevated levels may be up to three times more likely to be diagnosed with ovarian cancer.

Serum calcium can be detected and quantified using standard techniques, including absorption spectrometry, ion selective electrode, fluorescent detection, etc. The measured levels can be incorporated into an overall risk score, identifying women who should undergo further CA125 and ultrasound screening.
APPLICATIONS
  • Detecting ovarian cancer and possibly recurrence
  • Calculating an ovarian cancer risk score
KEY BENEFITS
  • Method is simple and effective.
  • Supports earlier diagnosis
  • Flags women who should undergo further, more intensive testing
ADDITIONAL INFORMATION
Publications
  • Schwartz G.G. and Skinner H.G. 2013. Prospective Studies of Total and Ionized Serum Calcium in Relation to Incident and Fatal Ovarian Cancer. Gynecol. Oncol. 129. 169-172.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or (608) 265-9861.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.